Statines in pregnancy
DOI:
https://doi.org/10.47196/diab.v56i3Sup.564Keywords:
estatines, pregnancyAbstract
Until a few years ago, the classification of the Food and Drug Administration (FDA) to indicate the level of risk of drugs on the fetus established five categories (A, B, C, D, X). Category X included contraindicated drugs, among which were statins. That is to say, there was a formal contraindication for statins to be used during pregnancy, or in women who could become pregnant, due to their possible teratogenic effects. Studies published after this categorization provided new data on the subject. In particular, they question the positive association between the use of statins in the embryogenic period and congenital malformations. Some studies have even shown that intrauterine exposure to statins favors prematurity and/or low birth weight.
References
-
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
